Michael Rosenzweig, DVM, PhD

Advisor

Michael is Executive Vice President at Capstan Therapeutics. In his most recent role as Entrepreneur-in-Residence at Raven, Michael worked closely with the RA Capital Management Investment Team to evaluate drug discovery platforms and initiate novel therapeutic programs. Michael has more than two decades of experience in immuno-oncology and immunology research in both large pharma and biotech settings. Prior to joining Raven, Michael was Associate Vice President at Merck Research Labs. In this position, he played a critical role in building Merck’s oncology pipeline into one of the most robust in cancer immunotherapy, focusing on a modality-agnostic strategy with a broad biology of targets and Keytruda combination strategies. He was also responsible for initiating the transition of the autoimmunity strategy from one based on systemic immunosuppression to a targeted immunomodulation approach. Prior to his time at Merck, Michael held discovery leadership roles at Immunext and Tolerx. Michael earned a DVM at the University of Pretoria and a PhD in Immunology at the University of Pennsylvania.